RZLT vs. MCRB, CTMX, SCTL, ADAG, NVCT, COYA, PDSB, INCR, RLMD, and IMUX
Should you be buying Rezolute stock or one of its competitors? The main competitors of Rezolute include Seres Therapeutics (MCRB), CytomX Therapeutics (CTMX), Societal CDMO (SCTL), Adagene (ADAG), Nuvectis Pharma (NVCT), Coya Therapeutics (COYA), PDS Biotechnology (PDSB), InterCure (INCR), Relmada Therapeutics (RLMD), and Immunic (IMUX). These companies are all part of the "pharmaceutical preparations" industry.
Seres Therapeutics (NASDAQ:MCRB) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, community ranking, media sentiment and valuation.
In the previous week, Rezolute had 7 more articles in the media than Seres Therapeutics. MarketBeat recorded 7 mentions for Rezolute and 0 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.58 beat Rezolute's score of 0.10 indicating that Rezolute is being referred to more favorably in the news media.
Rezolute's return on equity of 0.00% beat Seres Therapeutics' return on equity.
Rezolute has lower revenue, but higher earnings than Seres Therapeutics. Rezolute is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.
Seres Therapeutics has a beta of 2.23, suggesting that its share price is 123% more volatile than the S&P 500. Comparatively, Rezolute has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500.
Seres Therapeutics currently has a consensus price target of $6.50, indicating a potential upside of 766.90%. Rezolute has a consensus price target of $8.80, indicating a potential upside of 241.09%. Given Rezolute's higher possible upside, equities analysts plainly believe Seres Therapeutics is more favorable than Rezolute.
59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 83.0% of Rezolute shares are owned by institutional investors. 5.1% of Seres Therapeutics shares are owned by insiders. Comparatively, 18.2% of Rezolute shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Seres Therapeutics received 468 more outperform votes than Rezolute when rated by MarketBeat users. However, 75.00% of users gave Rezolute an outperform vote while only 72.40% of users gave Seres Therapeutics an outperform vote.
Summary
Seres Therapeutics beats Rezolute on 8 of the 15 factors compared between the two stocks.
Get Rezolute News Delivered to You Automatically
Sign up to receive the latest news and ratings for RZLT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RZLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rezolute Competitors List
Related Companies and Tools
